Escherichia colif respectively, can progress to the hemolytic-uremic syndrome. It has been hypothesized that circulating Shiga toxin, Shiga-like toxins, and endotoxins may contribute to the disease by directly damaging glomerular endothelial cells. The effects of these toxins on HeLa, Vero, and human vascular endothelial cells (EC) were examined. Confluent EC were sensitive to Shiga toxin but were at least 106 -fold less sensitive to the toxins than were Vero cells. Shiga toxin was the predominant cytotoxic factor. Lipopolysaccharides were not cytotoxic and did not augment Shiga toxin-mediated toxicity. Lower doses of Shiga toxin caused cytotoxicity when coincubated with tumor necrosis factor. The relative resistance of EC to Shiga toxin and Shiga-like toxins may be due to reduced toxin binding, as low levels of globotriaosylceramide (Gb3), the toxin-specific receptor, were found in EC membranes.
from the 28S rRNA component of the 60S eukaryotic ribosome complex [8, 9] . The B subunit mediates binding of the holotoxin to specific glycolipid receptors in mammalian cell membranes [10] [11] [12] [13] . Although the precise role of Shiga toxin and the SLTs in the pathogenesis of bacillary dysentery and hemorrhagic colitis, respectively, is not fully understood, there is now convincing evidence to suggest that the toxins are important virulence factors in the development of bloody, edematous vascular lesions of the colon [14] . The toxins may also participate in the direct killing of colonic epithelial cells and may provoke fluid secretion and diarrhea in the host [7] .
Perhaps the most serious sequela of colitis caused by S. dysenteriae type 1 or EHEC is the progression of the disease to the hemolytic-uremic syndrome (HUS), which is characterized by acute renal failure, thrombotic microangiopathy, and thrombocytopenia [15] . Histopathologic studies of the kidneys of HUS patients have shown profound alterations in the glomeruli. More specifically, glomerular endothelial cells (EC) appear swollen, and there is abundant fibrin deposition and inflammatory cell influx in the lumina of the glomeruli [16] . These observations, as well as the critical role of EC in maintaining normal blood flow [ 17] , have led to the concept that systemic Shiga toxin or SLTs may specifically target the glomerular EC for damage and thereby contribute to the development of HUS. In support of this hypothesis, Obrig et al. [18] showed that Shiga toxin preparations are cytotoxic for human umbilical vein EC (HUVEC) in vitro.
In the experiments reported here, we assessed the cytotoxic potential of crude Shiga toxin, SLT-II, and affinity-purified Shiga toxin for confluent human saphenous vein EC (HSVEC) and HUVEC monolayers. In addition, we compared Shiga toxin-mediated EC and Vero cell cytotoxicity and examined the role of lipopolysaccharides (LPS) and recombinant human tumor necrosis factor-a in direct EC cyto-toxicity. Finally, we analyzed toxin binding to intact EC and quantitated levels of toxin receptor in EC membranes.
Materials and Methods
Bacterial strains and plasmids. S. dysenteriae type 1 strain 3818T produces high levels of Shiga toxin and was isolated from a patient with severe dysentery in Central America [19] . E. coli 0157:H7 strain 933 produces both SLT-I and II and was isolated from an outbreak of hemorrhagic colitis in the United States [2, 5] . Toxins used in this study were derived from E. coli DH5a (Bethesda Research Laboratories, Gaithersburg, MD) transformed with recombinant plasmids containing the cloned toxin genes. E. coli (pLPSH3) harbors the plasmid pBR328 that contains the entire Shiga toxin operon on a 5.9-kb Bglll-Sall insert subcloned from pNAS 10 [4, 20] . E. coli (pLP32) harbors a Bluescribe vector (pBS[?] phagemid kit; Stratagene, La Jolla, CA) with a 3.0-kb Sphl-Kpnl fragment from pNN76 encoding SLT-II [21, 22] . Clones producing high levels of toxin were maintained under BL3 -f-EK1 containment [23] .
Toxin preparations. LPS were prepared from S. dysenteriae 3818T and E. coli 933 by the hot aqueous-phenol method of Westphal and Jann [24] . The pooled aqueous phases were dialyzed against nine changes of double-distilled, deionized HjO, concentrated 10-fold (Amicon, Danvers, MA), and lyophilized. LPS preparations contained ^ Mg/ml protein (BCA protein assay; Pierce Chemical, Rockford, IL). E. coli Ol 11:B4 LPS was purchased from Sigma Chemical (St. Louis). Concentrated crude Shiga toxin and SLT-II were prepared from E. coli (pLPSH3) and E. coli (pLP32), respectively. The strains were grown at 370C in 50 ml of Luria broth (LB) containing 250 Mg/ml ampicillin for 24 or 48 h with constant agitation. The bacteria were pelleted by centrifugation, washed, and resuspended in 5.0 ml of LB. The bacteria were disrupted by sonication and the lysates cleared by centrifugation at 12,000 g for 15 min. Toxins in the clarified lysates were concentrated by precipitation with 60(3d saturated ammonium sulfate. The precipitates were resuspended in 5.0 ml of PBS and dialyzed overnight against PBS. Toxins prepared in this manner reproducibly contained ~ 108 -109 CDso/ml when assessed by the Vero cell cytotoxicity assay. Purified Shiga toxin was prepared from this crude starting material as described [22, 25] . Briefly, crude toxin was passed over a DEAE-Sepharose column equilibrated with 0.05 M TRIS buffer and eluted with a gradient of 0-1.0 M NaCl in 0.05 M TRIS buffer. Fractions cytotoxic for Vero cells were pooled and passed over a chromatofocusing column. Cytotoxic fractions were pooled, dialyzed, and passed over an antitoxin affinity column. Shiga toxin was eluted with 0.05 M glycine, dialyzed against PBS, and stored at 40C until used. Purified Shiga toxin preparations contained k0. 1 ng/ml endotoxin as assessed by limulus amoebocyte lysate gelation (Endotect; Schwarz/Mann Biotech, Cleveland).
Recombinant human tumor necrosis factor-a (rhTNFa). rhTNFa (lot NBP-802A; 2.7 X 107 units/mg) was the gift of A. Creasey (Cetus, Emeryville, CA). Before use in cytotoxicity assays, the lyophilized cytokine was resuspended to 260 pg/ml in sterile pyrogen-free water (Travenol Laboratories, Deerfield, IL). The stock preparations were then diluted in growth medium as needed.
Tissue Cytotoxicity assays. The cytotoxicity of toxin preparations for Vero cells was determined as described [29] . Vero cells were plated at ~ 104 cells/well in 96-well plates and incubated overnight at 370C in 57c CO2. Toxin preparations were serially diluted in complete Eagle's MEM medium, and 100 pi of the dilutions was transferred to the cells. Incubation was continued for 48 h. The cells were fixed with formalin and stained with 0.137c crystal violet. Absorbance was measured at 620 nm. A 50% cytotoxic dose (CD5o) represents the reciprocal dilution of toxin necessary to kill 50^ of the Vero cells in a well. The cytotoxic potency of toxin preparations is defined as the number of CD50 per milliliter of toxin preparation. Cytotoxicity of toxin preparations for EC was assessed by hemocytometer counts or by spectrophotometry. EC were plated on the interior 24 wells of gelatin-coated 96-well plates at ~2 X 104 cells per well. Exterior wells were filled with PBS-CMF. When the cells reached confluence, fresh CM-BRE containing the toxin(s) to be assayed were added to triplicate wells in a total volume of 200 pi. Incubation was continued at 370C in 57c C02. Cells that subsequently detached from the gelatin substratum failed to exclude trypan blue, or after extensive washing, did not grow when recultured on gelatin-coated plates.
Viable cells were stained for counting in a hemocytometer by replacing the growth medium with 60 pi of 0.17c crystal violet in 0.1 M citric acid (pH 7.26). After the cells were incubated with the dye at 370C for 20 min, the wells were scraped with sterile pipette tips, and 15 /d of cell suspension was transferred to the hemocytometer. Stained nuclei were then counted. Cells were counted using a microtiter plate reader according to the method of Brasaemle and Attie [30] . Cells were washed with warm PBS-CMF, and 100 pi of methanol per well was added for 15 min at room temperature. The methanol was aspirated from the wells, the plates were air dried, and 100 pi of 0.17c crystal violet was added to each well for 5 min. After the dye was removed and the plates dried, each well was washed with HjO, and the stained cells were solubilized with 100 pi of 27c (wt/vol) sodium deoxycholate. The plates were heated in a microwave oven (Samsung MW5510; setting 2) for 1 min, and agitated (mini-orbital shaker, setting 6; Bellco Glass, Vineland, NJ) for 10 min. Absorbance was read at 570 nm. Cell counts were correlated by linear regression analysis of hemocytometer cgunts of stained nuclei against absorbance measurements of triplicate serial twofold dilutions of EC. This assay produced a linear standard curve between 1.5 X 103 and 6 X 104 cells per well (mean R value, .92).
Data were expressed as percentage of viability, which is defined as (number of cells Htoxin ? background/number of control cells ? background) X 100. Background absorbance was derived from staining blank wells. Control cells were incubated with CM-BRE only.
Neutralization assay. Dilutions of toxins were made in appropriate growth media in 96-well plates (100 pl/well), and 100 pi of anti-Shiga toxin monoclonal antibody (MAb 13C4) was added to each well. The plates were agitated, incubated at 370C in 57c CO2 for 1 h, and kept overnight at 40C. Toxin-antitoxin mixtures (100 pi) were then added to Vero cells or EC, and cytotoxicity was determined as described above. An isotypematched MAb directed against the B subunit of cholera toxin [31] did not affect cytotoxicity in this assay. Goat anti-mouse IgG labeled with 125I was used as secondary antibody. The plates were washed, air dried, and specific binding was visualized by autoradiography. Relative amounts of toxin-binding glycolipids were estimated from peak areas of densitometric scans obtained with a densitometer (CS9000U; Shimadzu, Kyoto, Japan) and compared with serial dilutions of the control glycolipid globotriaosylceramide (Gb3). Autoradiographs of several exposure times for each thin layer chromatography plate were scanned to ensure the peak areas were within the linear range of the densitometer.
Analysis of toxin binding to whole cells. A modification of an immunofluorescence protocol using a computer-assisted scanning laser instrument (ACAS 470; Meridian Instruments, Okemos, MI) was devised to compare Shiga toxin binding to EC versus Vero and HeLa cells [20, 32]. Cells were trypsinized and adjusted to ~5 X 105 cells/ml in cold diluent buffer (phenol red-free Earle's balanced salt solution [EBSS; GIBCO] contain
Statistical analysis. The significance of differences between means of samples was determined by Student's two-tailed t test. P < .025 was considered significant. (figure 1 A) . Cytotoxicity occurred within the first 24 h of incubation, and EC viability remained reduced relative to control cells over 72 h. When HUVEC were used as target cells, the kinetics and dose response of Shiga toxinmediated toxicity were essentially identical to those of HSVEC (data not shown). Treatment of both EC types with crude SLT-II preparations killed the cells in a manner similar to crude Shiga toxin (data not shown). Finally, treatment of both EC types with affinity-purified Shiga toxin resulted in killing that was similar to that observed with crude toxin preparations ( figure 1B) . Dilutions of the toxins were made based on cytotoxicity for Vero cells. From these data, we estimated that 1 EC CD50 was roughly equivalent to 107 Vero cell CD50, or ~ 1.4 X 10~8 M Shiga toxin. These results suggest, therefore, that while confluent human EC derived from large veins are sensitive to Shiga toxin, they are at least 106 -fold less susceptible than Vero cells.
Results

Role of Shiga toxin, SLT-II, and LPS in direct EC
The observation that purified Shiga toxin killed EC in a manner similar to crude toxin preparations suggested that Shiga toxin was the primary mediator of cytotoxicity for EC. However, the effects of small amounts of endotoxin present in the toxin preparations could not be discounted, especially in light of recent evidence that nanogram quantities of endotoxins can have profound effects on EC function [37-39]. To more fully assess the role of Shiga toxin in EC cytotoxicity, we incubated the cells with varying amounts of affinitypurified Shiga toxin in the presence or absence of anti-Shiga toxin MAb (table 1) . Even at the highest toxin concentration tested, cytotoxicity was completely neutralized by antitoxin antibody. Antibody alone had no effect on cell viability, and the addition of an irrelevant, isotype-matched MAb did not block Shiga toxin cell killing (data not shown). The observation that MAb directed against Shiga toxin neutralizes cytotoxicity provides further evidence in support of the concept that, in vitro, Shiga toxin is the predominant mediator of direct EC cytotoxicity.
In light of clinical evidence suggesting that patients with HUS are frequently endotoxemic [40] as well as histopatho- 
NOTE. Confluent EC were incubated for 24 or 72 h with the indicated doses of Shiga toxin, in the presence or absence of anti-Shiga toxin MAb. The number of substratum-adherent cells was determined as described in
Figure 2. Effect of Shiga toxin (ShT) versus lipopolysaccharides (LPS) on endothelial cell (EC) viability that was determined after confluent cells were incubated 48 h with ~ 1 EC 50% cytotoxic dose (1 EC CD50 ^ 107 Vero cell CD5o) of purified ShT only; 10 Mg/ml LPS derived from Escherichia coli 0111 :B4, E. coli 0157:H7 strain 933, or Shigella dysenteriae 3818T; or mixtures of 1 EC CD50 ShT and LPS. Error bars = SD. Differences between samples were analyzed by Student's two-tailed t test; P < .025 was significant. logic data suggesting that endotoxins may contribute to the pathologic changes in the kidney characteristic of HUS [41], we queried whether LPS might play a direct role on in vitro EC killing. We demonstrated that purified LPS derived from S. dysenteriae type 1 and EHEC strains were not directly cytotoxic for confluent human EC monolayers (figure 2) or Vero cells (data not shown) at doses as high as 10 pgjml. Furthermore, the coincubation of EC with 10-fold dilutions of LPS and a constant dose of affinity-purified Shiga toxin (~1 EC CD50) did not have a statistically significant effect on EC cytotoxicity in comparison with treatment with Shiga toxin alone (P ^ .025). Thus, while the presence of endotoxins in vivo may be an important factor in the pathogenesis of HUS, purified LPS alone does not appear to be a major determinant of direct EC cytotoxicity in vitro. LPS elicits the synthesis and secretion of TNFa by monocytes and macrophages. TNFa may have pleiotropic effects in vivo, and this cytokine has emerged as a central mediator in initiating and regulating the complex cascade of events that results in a procoagulant and proinflammatory state in the vasculature [42]. However, the contributory effect, if any, of TNFa in Shiga toxin-mediated direct EC cytotoxicity is not clear. We therefore coincubated EC with dilutions of Shiga toxin and rhTNFa and assessed EC cytotoxicity.
In the presence of 10 ng/ml rhTNFa, we detected an ~ 100fold reduction in the Shiga toxin EC CD50 (table 2) .
Comparative analysis of Shiga toxin and SLT-II binding to intact cells. Shiga toxin and SLTs bind to specific glycolipid receptors in the membranes of Vero or HeLa cells [10-13].
Antibody neutralization, competitive binding, and holotoxin dissolution studies have shown binding to be an essen-tial step in target cell intoxication and death [5, 43, 44] . Therefore, reduced binding of Shiga toxin and SLT-II to EC is one possible mechanism to explain the relative insensitivity of EC to the toxins.
To assess toxin binding to intact EC and to compare binding to control cells, we devised an indirect immunofluorescence assay using a computer-assisted laser scanner that converted fluorescence intensity into a pseudocolor spectrum.
To 
NOTE. Confluent endothelial cells were incubated in triplicate for 48 h with the indicated doses of Shiga toxin in presence or absence of rhTNFa. The number of substratum-adherent cells was determined as described in Materials and
Figure 3. Comparative analysis of Shiga toxin and Shiga-like toxin type II (SLT-II) binding to intact cells. Equivalent numbers of Vero cells, HeLa cells, and endothelial cells (EC) were treated with 109 Vero cell 50% cytotoxic doses of crude toxin preparations at 40C in the presence of NaN3. Bound toxins were detected with anti-toxin monoclonal antibodies and fluorescein-conjugated secondary antibody. The cells were outlined by simultaneous staining with a nonspecific fluorescent membrane probe. Fluorescence was measured using a Meridian ACAS 470 laser scanner in which fluorescence intensity was converted to the 15 color scale at right. Moving up the scale, colors represent increasing fluorescence intensity. A, Vero and HeLa cells (left and right panels, respectively) treated with Shiga toxin. B, EC treated with Shiga toxin (left) and membrane probe (right). C, EC treated with SLT-II (left) and membrane probe (right). D, EC treated with Escherichia coli DH5a concentrated sonicated lysate, (left) and membrane probe (right).
present in the fields. As a control, concentrated sonicated lysates were prepared from E. coli DH5a in a manner analogous to that used to concentrate Shiga toxin (see Materials and Methods). The control lysates showed no binding to EC ( figure 3D, left) . In addition, the deletion of primary or secondary antibody from the assay showed that nonspecific background fluorescence was very low in this procedure (data not shown). Therefore, the fluorescence detectable in Shiga toxin-treated cells is specifically due to toxin binding. These data suggest that one reason EC are less sensitive than Vero or HeLa cells to the cytotoxic effect of Shiga toxin may be low levels of toxin binding to the cells. lipid extracts (figure 4, lanes 6-15) . Glycolipid standards were used to compare the glycolipids present in each cell line ( figure 4, lanes 1-5, 16) . In contrast to Vero and HeLa cells, the amount of toxin-binding glycolipids detected in EC membrane extracts prepared from equivalent cell wet weights was greatly reduced. Bound toxin was detected with Shiga toxin-specific MAb and 125I-labeled goat anti-mouse IgG antibody. Since the amount of toxin-specific glycolipids present in membrane extracts was previously shown to correlate directly with the amount of bound toxin [45] , we quanti-tated the relative amounts of toxin-binding glycolipids by direct densitometric scanning of the autoradiographs. HU-VEC and HSVEC contained 0.06 and 0.03 nM Gb3/mg of cells, respectively. In contrast, Vero and HeLa cells contained 80 and 25 nM Gb3/mg of cells, respectively. Thus, the diminished toxin-binding glycolipid content of EC compared with Vero and HeLa cells directly correlated with reduced Shiga toxin sensitivity and toxin binding.
Comparative quantitative analysis of toxin-specific glycolipid receptors in EC. Toxin-binding glycolipids present in Vero and HeLa cells and EC were detected by the direct binding of saturating amounts of Shiga toxin to thin-layer chromatograms of serial dilutions of membrane total glyco-
Discussion
The experiments reported here were designed to examine the role of crude or purified Shiga toxin, SLT-II, LPS, and recombinant cytokines in killing confluent human vascular endothelial cells and to compare the EC cytotoxicity with that of other cell lines. The incubation of EC with purified Shiga toxin resulted in a reduction in the numbers of viable cells remaining attached to gelatin-coated dishes, and this activity was neutralized by anti-Shiga toxin MAb, suggesting that Shiga toxin was the primary mediator of cytotoxicity in vitro. These results support and extend the findings of Obrig et al. [18] , who demonstrated that rabbit polyclonal anti-Shiga toxin antibodies, as well as heat denaturation, totally neutralize the EC cytotoxic potential of Shiga toxin preparations. These investigators also showed, however, that Shiga toxin, to a dose of 10 . 10' CD50, figure 1 ). In addition, we isolated viable EC, even when the cells were incubated with -10 EC CD50 of Shiga toxin. Although previous studies have clearly demonstrated differential cytotoxicity between confluent and nonconfluent HUVEC [18] , our data suggest that even within a population of confluent EC, there may be heterogeneity in terms of susceptibility to Shiga toxin.
Several lines of evidence suggest that endotoxins may contribute to the development of HUS. Bertani et al. [41] demonstrated that when rabbits were infused with E. coli 0111:B4 LPS, marked damage to glomerular EC became apparent within 5 min. Changes in EC morphology preceded polymorphonuclear cell infiltration and fibrin deposition. These changes were consistent with those seen in the kidneys of HUS patients [16] . Barrett et al. [48] showed that a single sublethal dose of endotoxin given to rabbits 3 days after the initiation of continuous SLT-II infusion enhances the lethal effect of the toxin. In the in vitro cytotoxicity assays reported here, however, purified LPS derived from S. dysenteriae type 1 or EHEC strains was not directly cytotoxic for EC at doses as high as 10 Ag/ml. This finding is in accordance with earlier studies showing that HUVEC are refractory to both LPS-mediated direct cytotoxicity and changes in EC function at doses as high as 100 ,g/ml [49, 50] . In addition, we have shown that the addition of anti-Shiga toxin MAb to crude toxin preparations neutralizes cytotoxicity, and the coincubation of EC with LPS and purified Shiga toxin neither enhanced nor inhibited EC cytotoxicity. However, the correlation of our in vitro cytotoxicity data with animal models of HUS should be made with caution. The capacity of endotoxins to mediate alterations in cellular functions, particularly through the elicitation of endogenous cytokines, is now well documented [42, 51] . Thus, the contributory effect of endotoxins in HUS may be mediated through changes in EC or inflammatory cell functions that have yet to be fully elucidated.
Our data suggest that in the presence of the cytokine TNFa, the Shiga toxin EC CD50 may be reduced from ~ lO"8 M to as low as ~ lO"10 M (table 2) . Although free Shiga toxin or SLTs in human sera have not been quantitated, it is not unreasonable to speculate that this lower dose of toxin may be in the physiologically relevant range [52] . In addition, Shiga toxin may exacerbate any cytotoxic effects mediated directly by cytokines. rhTNFa at 20 ng/ml or recombinant human interleukin-10 at 100 pg/ml have been demonstrated not to be directly cytotoxic for HUVEC [53] . However, in the presence of the protein synthesis inhibitor cycloheximide or the RNA synthesis inhibitor actinomycin D, HUVEC have been shown to be sensitized to the cytotoxic effects of these cytokines [53] . Therefore, by inhibiting de novo protein synthesis, Shiga toxin and SLTs may act to block the protective mechanism(s) necessary to overcome cytokine-mediated direct cytotoxicity.
We used an indirect immunofluorescence assay to monitor the binding of Shiga toxin to EC. Toxin-specific binding to EC was reduced relative to Vero and HeLa cells. We also noted cell-to-cell variations in toxin binding when Vero or HeLa cells or EC were treated with equivalent doses of Shiga toxin. Again, this suggests that the cells may consist of heterogeneous populations in terms of the capacity to bind Shiga toxin. Toxin binding studies using Shiga toxin-sensitive and resistant HeLa cell lines have shown that 10-fold differences in toxin binding sites can produce 109 -fold variability in toxin sensitivity [46, 47] . Thus, the minute differences in fluorescence we observed among cells in the toxin binding experiments may represent profound differences in Shiga toxin sensitivity. To more directly compare differences in toxin binding, we examined the glycolipid components of the cell membranes. Both EC types contained ~ 1000-fold less Gb3 than did Vero cells. Thus, the relative insensitivity of human EC derived from large veins may be directly correlated with reduced numbers of toxin-specific membrane receptors, and our data support earlier studies showing a correlation of Shiga toxin sensitivity with membrane Gb3 content [45, 47, 54] .
Our data demonstrating the relative insensitivity of human vascular EC to Shiga toxin and the paucity of toxin-specific membrane receptors suggest that the use of these cells may not represent the most appropriate in vitro model of HUS. Histopathologic studies have shown, however, that glomerular EC damage is a hallmark of HUS [16, 41] . Boyd and Lingwood [45] showed that Gb3 is the predominant neutral glycolipid in human renal tissue; their values were ~2-to 30-fold greater than the amount of Gb3 we detected in EC. Although the amount of glycolipid in a complex tissue sample may not accurately reflect the relative amount in a particular cell type, the data suggest that EC derived from large veins may differ in their toxin-receptor content from glomerular endothelial cells. Finally, it is important to note that human vascular EC and glomerular EC are functionally and morphologically distinct cells. Glomerular EC are highly fenestrated and coated with a sialoglycoprotein-rich anionic glycocalix [55] . The structural and functional differences in EC may include differential responses to Shiga toxin or LPS. There is one report that endotoxins are directly cytotoxic for human glomerular endothelial cells [56] . Further studies on the effect of Shiga toxin and endotoxin on human glomerular cells are clearly warranted and are currently in progress in our laboratory.
